Cargando…
The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study
BACKGROUND: Using a pharmacokinetic (PK)-guided approach to personalize the dose and frequency of prophylactic treatment can help achieve and maintain targeted factor VIII (FVIII) trough levels in patients with hemophilia A. OBJECTIVE: Investigate clinical and healthcare resource use outcomes in pat...
Autores principales: | Ferri Grazzi, Enrico, Sun, Shawn X, Burke, Tom, O’Hara, Jamie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507282/ https://www.ncbi.nlm.nih.gov/pubmed/36157322 http://dx.doi.org/10.2147/JBM.S363028 |
Ejemplares similares
-
Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys
por: Burke, Tom, et al.
Publicado: (2021) -
Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe
por: Burke, Tom, et al.
Publicado: (2021) -
The cost of severe haemophilia in Europe: the CHESS study
por: O’Hara, Jamie, et al.
Publicado: (2017) -
The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study
por: Young, Lisa, et al.
Publicado: (2023) -
Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis
por: O’Hara, Jamie, et al.
Publicado: (2021)